S299: ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE, FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS OF A RANDOMIZED, OPEN-LABEL PHASE II STUDY

• Yan Shi,
• Hu Zhou,
• Ruibin Huang,
• Fang Wang,
• Heng Mei,
• Lie Lin,
• Jingming Guo,
• Xin Zhou,
• Zhenyu LI,
• Yaorong Liu,
• Sichen LI,
• Wei Zhou,
• Ming Hou

Affiliations

Yan Shi

1 Qilu Hospital, Cheeloo College of Medicine, Shandong University, Department of Hematology, Jinan, China

Hu Zhou

2 Henan Cancer Hospital, Department of Hematology, Zhengzhou, China

Ruibin Huang

3 The First Affiliated Hospital of Nanchang University, Department of Hematology, Nanchang, China

Fang Wang

4 The First Affiliated Hospital of Zhengzhou University, Department of Hematology, Zhengzhou, China

Heng Mei

5 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Hematology, Wuhan, China

Lie Lin

6 Hainan General Hospital, Department of Hematology, Haikou, China

Jingming Guo

7 Yichang Central People’s Hospital, Department of Hematology, Yichang, China

Xin Zhou

8 Wuxi People’s Hospital, Department of Hematology, Wuxi, China

Zhenyu LI

9 The affiliated Hospital of Xuzhou Medical University, Department of Hematology, Xuzhou, China

Yaorong Liu

10 InnoCare Pharma Limited, Department of Medical Research, Beijing, China

Sichen LI

11 InnoCare Pharma Limited, Department of Biostatics, Beijing, China

Wei Zhou

10 InnoCare Pharma Limited, Department of Medical Research, Beijing, China

Ming Hou

1 Qilu Hospital, Cheeloo College of Medicine, Shandong University, Department of Hematology, Jinan, China